A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).
Herbert Hurwitz
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech; Novartis; Pfizer; Roche; Sanofi
Research Funding - Bristol-Myers Squibb; Genentech; Novartis; Pfizer; Roche; Sanofi
Nikhil Uppal
No relevant relationships to disclose
Stephanie Ann Wagner
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
J. Thaddeus Beck
Research Funding - Incyte
Seaborn Wade
No relevant relationships to disclose
John J. Nemunaitis
No relevant relationships to disclose
Philip J. Stella
No relevant relationships to disclose
J. Marc Pipas
Research Funding - Incyte
Zev A. Wainberg
No relevant relationships to disclose
Robert Manges
Research Funding - Incyte
William M. Garrett
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Deborah S. Hunter
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Jason Clark
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Lance Leopold
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Richard S. Levy
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Victor Sandor
Employment or Leadership Position - Incyte
Stock Ownership - Incyte